1076189-11-1Relevant articles and documents
Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2
Fujimoto, Kazuki,Matsuoka, Eriko,Asada, Naoya,Tadano, Genta,Yamamoto, Takahiko,Nakahara, Kenji,Fuchino, Kouki,Ito, Hisanori,Kanegawa, Naoki,Moechars, Diederik,Gijsen, Harrie J. M.,Kusakabe, Ken-Ichi
, p. 5080 - 5095 (2019)
BACE1 inhibitors hold potential as agents in disease-modifying treatment for Alzheimer's disease. BACE2 cleaves the melanocyte protein PMEL in pigment cells of the skin and eye, generating melanin pigments. This role of BACE2 implies that nonselective and
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALZHEIMER'S DISEASE
-
Page/Page column 76, (2010/03/02)
A pharmaceutical composition for treating Alzheimer's disease containing a compound represented by the general formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; E is lower alkylene,